Grant Number:	5R01CA240602-05 Interpret this number
Primary Investigator:	Brash, Douglas
Organization:	Yale University
Project Title:	Using Clonal and Non-Clonal Uv Signature Mutations to Predict Skin Cancer Risk
Fiscal Year:	2023

Project Summary Cancer prevention programs can reduce cancer incidence, cancer-related deaths, and healthcare costs. Yet population-level cancer prevention programs are expensive and difficult to implement, and their benefit must be weighed against the risk of overdiagnosis and harms associated with followup care. An emerging view is that prevention efforts ought to be focused on the populations at highest risk. In an era of precision medicine, Precision Prevention would objectively measure a person's past exposure to a risk factor as a factor in predicting that individual's risk of cancer or occupational disease. High-risk individuals would then be monitored frequently by a specialist. Skin cancers are an ideal starting point because they are nearly as frequent as all other human cancers combined, the carcinogen is known to usually be ultraviolet light (UV), the carcinogenic DNA photoproduct is known to be the cyclobutane pyrimidine dimer (CPD), the CPD leaves telltale UV signature mutations, and normal sun-exposed tissue is readily accessible. The present project takes advantage of three recent technical advances in order to assess individual risk and answer basic questions about using UV-induced mutations for risk prediction. First, the project uses a nonscarring surfactant-based skin biopsy method (Surfactant-mediated Tissue Acquisition for Molecular Profiling, STAMP) in order to sample multiple non-diseased sites from a single subject and to facilitate recruitment. Non-diseased sites reflect the initial UV exposure more closely than tumor sites. Second, mutation detection sensitivity is enhanced by adapting cutting-edge techniques developed for liquid biopsies, including multiplexed genome targets and error-correction techniques that bring the detection limit down to 1 mutation per million bases. Third, the project takes advantage of recently-identified "genomic dosimeters" that are ~100 fold more sensitive to UV than a typical CPD target in the genome. The project begins by adapting these methods to small samples of human skin, then determines how mutations in genomic dosimeters vary with UV exposure to normal skin, and finally determines how the incidence of several types of skin cancer varies with the genomic dosimeter mutation level in sun-exposed normal skin, in order to construct a cancer-probability metric. The results will establish a route to Precision Prevention using UV signature mutations.





None